3bc3: Difference between revisions
Jump to navigation
Jump to search
m Protected "3bc3" [edit=sysop:move=sysop] |
No edit summary |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Exploring inhibitor binding at the S subsites of cathepsin L== | |||
<StructureSection load='3bc3' size='340' side='right'caption='[[3bc3]], [[Resolution|resolution]] 2.20Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3bc3]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3BC3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3BC3 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CSD:3-SULFINOALANINE'>CSD</scene>, <scene name='pdbligand=OPT:S-BENZYL-N-(BIPHENYL-4-YLACETYL)-L-CYSTEINYL-N~5~-(DIAMINOMETHYL)-D-ORNITHYL-N-(2-PHENYLETHYL)-L-TYROSINAMIDE'>OPT</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3bc3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3bc3 OCA], [https://pdbe.org/3bc3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3bc3 RCSB], [https://www.ebi.ac.uk/pdbsum/3bc3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3bc3 ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/CATL1_HUMAN CATL1_HUMAN] Important for the overall degradation of proteins in lysosomes. | |||
== Evolutionary Conservation == | |||
[[Image:Consurf_key_small.gif|200px|right]] | |||
Check<jmol> | |||
<jmolCheckbox> | |||
<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/bc/3bc3_consurf.spt"</scriptWhenChecked> | |||
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | |||
<text>to colour the structure by Evolutionary Conservation</text> | |||
</jmolCheckbox> | |||
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=3bc3 ConSurf]. | |||
<div style="clear:both"></div> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
We report a series of noncovalent, reversible inhibitors of cathepsin L that have been designed to explore additional binding interactions with the S' subsites. The design was based on our previously reported crystal structure that suggested the possibility of engineering increased interactions with the S' subsites ( Chowdhury et al. J. Med. Chem. 2002, 45, 5321-5329 ). A representative of these new inhibitors has been co-crystallized with mature cathepsin L, and the structure has been solved and refined at 2.2 A. The inhibitors described in this work extend farther into the S' subsites of cathepsins than any inhibitors reported in the literature thus far. These interactions appear to make use of a S3' subsite that can potentially be exploited for enhanced specificity and/or affinity. | |||
Exploring inhibitor binding at the s' subsites of cathepsin L.,Chowdhury SF, Joseph L, Kumar S, Tulsidas SR, Bhat S, Ziomek E, Menard R, Sivaraman J, Purisima EO J Med Chem. 2008 Mar 13;51(5):1361-8. Epub 2008 Feb 16. PMID:18278855<ref>PMID:18278855</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 3bc3" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
*[[Cathepsin|Cathepsin]] | *[[Cathepsin 3D structures|Cathepsin 3D structures]] | ||
== References == | |||
== | <references/> | ||
< | __TOC__ | ||
</StructureSection> | |||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Bhat | [[Category: Large Structures]] | ||
[[Category: Chowdhury | [[Category: Bhat S]] | ||
[[Category: Joseph | [[Category: Chowdhury SF]] | ||
[[Category: Kumar | [[Category: Joseph L]] | ||
[[Category: Nard | [[Category: Kumar S]] | ||
[[Category: Purisima | [[Category: Nard RM]] | ||
[[Category: Sivaraman | [[Category: Purisima EO]] | ||
[[Category: Tulsidas | [[Category: Sivaraman J]] | ||
[[Category: Ziomek | [[Category: Tulsidas SR]] | ||
[[Category: Ziomek E]] | |||
Latest revision as of 15:06, 30 August 2023
Exploring inhibitor binding at the S subsites of cathepsin LExploring inhibitor binding at the S subsites of cathepsin L
Structural highlights
FunctionCATL1_HUMAN Important for the overall degradation of proteins in lysosomes. Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedWe report a series of noncovalent, reversible inhibitors of cathepsin L that have been designed to explore additional binding interactions with the S' subsites. The design was based on our previously reported crystal structure that suggested the possibility of engineering increased interactions with the S' subsites ( Chowdhury et al. J. Med. Chem. 2002, 45, 5321-5329 ). A representative of these new inhibitors has been co-crystallized with mature cathepsin L, and the structure has been solved and refined at 2.2 A. The inhibitors described in this work extend farther into the S' subsites of cathepsins than any inhibitors reported in the literature thus far. These interactions appear to make use of a S3' subsite that can potentially be exploited for enhanced specificity and/or affinity. Exploring inhibitor binding at the s' subsites of cathepsin L.,Chowdhury SF, Joseph L, Kumar S, Tulsidas SR, Bhat S, Ziomek E, Menard R, Sivaraman J, Purisima EO J Med Chem. 2008 Mar 13;51(5):1361-8. Epub 2008 Feb 16. PMID:18278855[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||